Background Re-challenge of erlotinib after gefitinib failure is reported to yield some benefit
in patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor …

Background Gefitinib and erlotinib are two orally active epidermal growth factor receptor
tyrosine kinase inhibitors used in the treatment of advanced non-small cell lung cancer …

Background Gefitinib is widely used in the treatment of advanced non-small cell lung cancer
(NSCLC). However, only a small number of reports have described initial failure sites in …

Objective: We describe the use of systemic therapy in advanced cancer patients admitted to
an acute care hospital, with a focus on targeted therapy. We aim to spotlight the utilization of …

Purpose Chemotherapy is the mainstay treatment for advanced non-small cell lung cancer
(NSCLC). Gefitinib, an epidermal growth factor receptor—tyrosine kinase inhibitor (EGFR …

Erlotinib and gefitinib are among the most widely researched, used and available
molecularly targeted therapies for treatment of advanced non-small cell lung cancer …

The outcomes of first-generation EGFR-TKIs (Gefitnib and Erlotinib) have shown great
advantages over traditional treatment strategies in patients with non-small cell lung cancer …

The activity of erlotinib after gefitinib failure in non-small cell lung cancer patients with all
four favorable clinical factors including female, never smoker, Asian, and adenocarcinoma …

Purpose To evaluate the efficacy and safety of erlotinib in advanced non-small-cell lung
cancer after failure of gefitinib treatment. Patients and methods Patients with advanced or …

Methods: Forty-five patients with NSCLC who were treated with erlotinib following gefitinib
failure at Seoul National University Hospital between August 2005 and November 2011 …